Evidence map›Paper›PMID 38038177›Full record

ArticleAnnals of the Royal College of Surgeons of England2024

Peritoneal malignancy in the global COVID-19 pandemic: experience of recovery and restoration in a high-volume centre through NHS and independent sector collaboration.

E J Arbuthnot, J Parker, T Cecil, F Mohamed, R Williams, M Page, B Moran

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the Royal College of Surgeons of England, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

E J ArbuthnotPeritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust, UK.
J ParkerPeritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust, UK.
T CecilPeritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust, UK.
F MohamedPeritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust, UK.
R WilliamsPeritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust, UK.
M PageHampshire Clinic, UK.
B MoranPeritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust, UK.
Hampshire Hospitals NHS Foundation Trust · GBLondon Clinic · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTreatment of peritoneal malignancy with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) requires substantial critical care, theatre and nursing resources. The COVID-19 pandemic caused challenges in providing a high volume, tertiary referral service.

methodsWe reviewed data on referrals and operations performed in a tertiary referral centre in both NHS and independent sector settings. The impact of COVID-19 on activity was assessed using 2019 as a benchmark.

resultsNew patient referrals were similar, with 891 in 2019 compared with 833 in 2020. Delivery of CRS and HIPEC operations were initially impacted by COVID-19. NHS and independent sector collaboration facilitated recovery, with 284 patients treated in 2020 compared with 280 in 2019.

conclusionsClose collaboration and structural organisation between the clinical and management teams in the NHS and independent sectors facilitated recovery and restoration of a complex tertiary referral service for peritoneal malignancy during the COVID pandemic.

Indexed as

COVID-19Hyperthermia, InducedPeritoneal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCytoreduction Surgical ProceduresHumansPandemicsRetrospective StudiesState MedicineSurvival RateCOVID-19Independent sectorPeritoneal malignancyService provision

Identifiers

PMID38038177
PMCPMC10981979
OpenAlexW4389236858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.